1359 NTX-0471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA expressed in-vivo biologics
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
格式: | 文件 |
语言: | English |
出版: |
BMJ Publishing Group
2023-11-01
|
丛编: | Journal for ImmunoTherapy of Cancer |